Lanier Biotherapeutics advances medical treatments to improve quality of living
We discover and develop antibody treatments to restore and improve better health: seeing, breathing, and believing!
A portfolio in focus
Seeing the bigger picture
The Ideal Treatment for Checkpoint Inhibitor Pneumonitis (CIP)
Protection from pulmonary fibrosis with tumor suppression
Type 2 Inflammation / Fibrosis
Moderate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment
A portfolio in focus
Seeing the bigger picture
Retinal
Biobetter multifunctional anti-VEGF antibodies.
Type 2 Inflammation
Moderate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment.
Immuno-Oncology
Proprietary antibody offerings.
MT-6402 in the clinic with Molecular Templates.
Meet our team
Lanier Biotherapeutics is composed of some of the best minds in biotherapeutics. Visionaries with decades of experience and a dedication to advancing treatment for retinal, dermatological and respiratory diseases.
Daniel White
Chief Executive Officer & Director
Kirby Alton
Chairman
Martin Simonetti
Director
Christopher McLeod
Director
Investors
Lanier Biotherapeutics is funded by a group of visionary private investors
If you are interested in further exploring as an investor, please contact us.
Connect with us
Headquarters:
P.O. Box 1071
Jefferson, GA 30549
Jefferson, GA 30549
Lab:
150 Technology Parkway
Room #130
Peachtree Corners, GA 30092